公开(公告)号：US20180263967A1

公开(公告)日：2018-09-20

申请号：US15754934

申请日：2016-08-24

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Akira KAIEDA ,  Naoki ISHII ,  Hiroshi NARA ,  Masato YOSHIKAWA ,  Masaki DAINI

IPC分类号： A61K31/454 ,  A61K31/4545 ,  A61K31/5377 ,  A61P29/00

CPC分类号： A61K31/454 ,  A61K31/4545 ,  A61K31/5377 ,  A61P29/00 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

摘要： The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of inflammatory disease and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20170015655A1

公开(公告)日：2017-01-19

申请号：US15210965

申请日：2016-07-15

申请人： Takeda Pharmaceutical Company Limited

发明人： Akira KAIEDA ,  Masashi TOYOFUKU ,  Masaki DAINI ,  Hiroshi NARA ,  Masato YOSHIKAWA ,  Naoki ISHII ,  Kousuke HIDAKA

IPC分类号： C07D413/14 ,  C07D417/14 ,  C07D491/08 ,  C07D491/107 ,  C07D413/04 ,  C07D471/04

CPC分类号： C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04 ,  C07D491/08 ,  C07D491/107 ,  C07D498/08

摘要： The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

摘要翻译： 其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US20160251352A1

公开(公告)日：2016-09-01

申请号：US15148276

申请日：2016-05-06

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Hiroshi NARA ,  Masaki DAINI ,  Akira KAIEDA ,  Taku KAMEI ,  Toshihiro IMAEDA ,  Fumiaki KIKUCHI

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20210024512A1

公开(公告)日：2021-01-28

申请号：US17043162

申请日：2019-03-28

申请人： Kyoto University ,  Takeda Pharmaceutical Company Limited

发明人： Yoshinori YOSHIDA ,  Kenji MIKI ,  Akira KAIEDA ,  Shigeru KONDO ,  Hiroshi NARA ,  Yoshinori IKEURA

IPC分类号： C07D409/14 ,  C07D403/04

摘要： The present invention provides a heterocyclic compound having an activity to promote the maturation of a cardiomyocyte.
A compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof has an activity to promote the maturation of a cardiomyocyte, and is useful as a cardiomyocyte maturation promoter.

公开(公告)号：US20190008836A1

公开(公告)日：2019-01-10

申请号：US15745290

申请日：2016-07-15

申请人： Takeda Pharmaceutical Company Limited

发明人： Akira KAIEDA ,  Masaki DAINI ,  Hiroshi NARA ,  Masato YOSHIKAWA ,  Naoki ISHII ,  Masashi TOYOFUKU ,  Kousuke HIDAKA

IPC分类号： A61K31/437 ,  A61P25/28 ,  A61K31/4245 ,  A61K31/4035 ,  A61K31/4439

CPC分类号： A61K31/437 ,  A61K31/4035 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61P25/28 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

摘要： The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.